Tyra Biosciences, Inc. (TYRA) News
Filter TYRA News Items
TYRA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest TYRA News From Around the Web
Below are the latest news stories about Tyra Biosciences Inc that investors may wish to consider to help them evaluate TYRA as an investment opportunity.
Tyra Biosciences surges 14% as owner Boxer Capital buys 125,000 sharesNo summary available. |
Tyra Biosciences Inc (NASDAQ:TYRA) Major Shareholder Boxer Capital, Llc Acquires 125,000 SharesTyra Biosciences Inc (NASDAQ:TYRA) major shareholder Boxer Capital, Llc acquired 125,000 shares of the businesss stock in a transaction that occurred on Friday, December 17th. The stock was bought at an average cost of $13.12 per share, for a total transaction of $1,640,000.00. The purchase was disclosed in a filing with the Securities & Exchange [] |
Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ...Investment company Boxer Capital, Llc (Current Portfolio) buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, Fulcrum Therapeutics Inc, Turning Point Therapeutics Inc, sells Seagen Inc, Amarin Corp PLC, Therapeutics Acquisition Corp, , Agenus Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Boxer Capital, Llc. |
Head-To-Head Review: Tyra Biosciences (NASDAQ:TYRA) vs. Gain Therapeutics (NASDAQ:GANX)Tyra Biosciences (NASDAQ:TYRA) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings. Insider and Institutional Ownership 51.6% of Tyra Biosciences shares are held by institutional investors. Comparatively, [] The post Head-To-Head Review: Tyra Biosciences (NASDAQ:TYRA) vs. Gain Therapeutics (NASDAQ:GANX) appeared first on ETF Daily News . |
Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made... |
Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up to $17.26Tyra Biosciences Inc (NASDAQ:TYRA)s share price gapped up prior to trading on Thursday . The stock had previously closed at $17.26, but opened at $17.74. Tyra Biosciences shares last traded at $17.51, with a volume of 205 shares trading hands. A number of equities research analysts have commented on TYRA shares. Jefferies Financial Group reiterated [] The post Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up to $17.26 appeared first on ETF Daily News . |
Tyra Biosciences (NASDAQ:TYRA) vs. Gain Therapeutics (NASDAQ:GANX) Financial ContrastTyra Biosciences (NASDAQ:TYRA) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends and institutional ownership. Analyst Recommendations This is a breakdown of recent recommendations for Tyra Biosciences and Gain Therapeutics, [] |
-$0.21 EPS Expected for Tyra Biosciences Inc (NASDAQ:TYRA) This QuarterWall Street brokerages forecast that Tyra Biosciences Inc (NASDAQ:TYRA) will announce earnings of ($0.21) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Tyra Biosciences earnings, with the lowest EPS estimate coming in at ($0.24) and the highest estimate coming in at ($0.19). The business is expected to [] |
Tyra Biosciences (NASDAQ:TYRA) Shares Gap Down to $21.00Tyra Biosciences Inc (NASDAQ:TYRA)s stock price gapped down prior to trading on Friday . The stock had previously closed at $21.00, but opened at $19.47. Tyra Biosciences shares last traded at $18.33, with a volume of 315 shares changing hands. Several equities analysts recently commented on TYRA shares. Jefferies Financial Group reiterated a hold rating [] |
Zacks: Analysts Expect Tyra Biosciences Inc (NASDAQ:TYRA) to Announce -$0.21 Earnings Per ShareWall Street brokerages expect Tyra Biosciences Inc (NASDAQ:TYRA) to report ($0.21) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Tyra Biosciences’ earnings. The lowest EPS estimate is ($0.24) and the highest is ($0.19). The business is scheduled to announce its next quarterly earnings results […] |